EGFR and non-small cell lung carcinoma: We used samples (prepared by Molecular MD) that contained human genomic DNA isolated from approximately 6,000 wild-type cells and different amounts of human genomic DNA isolated from cells possessing the EGFR T790M single-nucleotide polymorphism, which is another mutation whose presence in non-small-cell lung cancer predicts resistance to tyrosine kinase inhibitors [27].